Immunization Forecasts in US
Ending the pandemic crisis won’t be quick or easy. Vaccines may initially slow deaths among those with chronic conditions. But the logistical, production and public education challenges of immunizing 60% to 70% of national populations -- the level the World Health Organization says is needed to achieve herd immunity -- will be a time-consuming and troublesome process. The world will still need masks, social distancing, widespread testing and effective new therapies to keep the virus at bay, public-health specialists say. Current Vaccine Candidates in US C ompany / Candidate Current Clinical Trial Phase Number of Doses Likely Needed for Full Course Notes AstraZeneca AZD1222 Adenovirus-vector vaccine Phase 3 2 doses , injected Supports advanced clinical studies, vaccine manufacturing technology transfer, process developm...